{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:16:16Z","timestamp":1793247376018,"version":"4.5.0"},"reference-count":103,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>Contemporary antiretroviral therapy (ART) regimens have high barriers to the development of drug resistance. However, resistance to earlier antiretrovirals and uncommon cases of resistance to contemporary ART illustrate the continued need for good clinical management of HIV drug resistance. Here, we describe HIV drug-resistance mechanisms, the interaction of HIV drug-resistant mutations and the patterns of drug resistance to contemporary ART. We then provide guidance on the management of HIV drug resistance, including how to limit the development of resistance and manage virologic failure that is complicated by resistance. To complement this, links to resources and treatment guidelines are provided that can assist with the interpretation of HIV drug resistance test results and optimal ART selection in the clinic.<\/jats:p>","DOI":"10.1177\/13596535231201162","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T23:41:48Z","timestamp":1695685308000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":73,"title":["HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5730-3625","authenticated-orcid":false,"given":"Andrew","family":"Carr","sequence":"first","affiliation":[{"name":"HIV and Immunology Unit, St Vincent's Hospital, Sydney, NSW, Australia"},{"name":"University of New South Wales, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola E","family":"Mackie","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Paredes","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Germans Trias i Pujol, Barcelona, Spain"},{"name":"IrsiCaixa AIDS Research Institute, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiat","family":"Ruxrungtham","sequence":"additional","affiliation":[{"name":"Chula Vaccine Research Center (Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"},{"name":"School of Global Health, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"},{"name":"The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS Research Centre, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"key":"bibr1-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2016.08.031"},{"key":"bibr2-13596535231201162","volume-title":"EACS guidelines version 11.1","author":"European AIDS Clinical Society","year":"2022"},{"key":"bibr3-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab481"},{"key":"bibr4-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2019.0111"},{"key":"bibr5-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-017-0360-7"},{"key":"bibr6-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02425-17"},{"key":"bibr7-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003070"},{"key":"bibr8-13596535231201162","first-page":"177","volume":"73","author":"Castagna A","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"bibr9-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa202"},{"key":"bibr10-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2007.0173"},{"key":"bibr11-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis750"},{"key":"bibr12-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1080\/25787489.2020.1794439"},{"key":"bibr13-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001494"},{"key":"bibr14-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0440-3"},{"key":"bibr15-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz256"},{"key":"bibr16-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix137"},{"key":"bibr17-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.0c00967"},{"key":"bibr18-13596535231201162","doi-asserted-by":"publisher","DOI":"10.3390\/v6104095"},{"key":"bibr19-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002251"},{"key":"bibr20-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy463"},{"key":"bibr21-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13288"},{"key":"bibr22-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2013.03.014"},{"key":"bibr23-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2011.03.038"},{"key":"bibr24-13596535231201162","first-page":"67","volume":"10","author":"Shafer RW","year":"2008","journal-title":"AIDS Rev"},{"key":"bibr25-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00922-17"},{"key":"bibr26-13596535231201162","unstructured":"Hikichi Y, Groebner JL, Wiegand A, et al. Mutations outside integrase lead to high-level resistance to dolutegravir. In: Conference on Retroviruses and Oppurtunistic Infections (CROI). Seattle, Washington. 2023."},{"key":"bibr27-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01741-15"},{"key":"bibr28-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2019.06.010"},{"key":"bibr29-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02237-10"},{"key":"bibr30-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003097"},{"key":"bibr31-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01804-22"},{"key":"bibr32-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103593"},{"key":"bibr33-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab583"},{"key":"bibr34-13596535231201162","volume-title":"INSTI resistance notes","author":"Stanford University HIV Drug Resistance Database","year":"2022"},{"key":"bibr35-13596535231201162","volume-title":"NRTI resistance notes","author":"Stanford University HIV Drug Resistance Database","year":"2022"},{"key":"bibr36-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1126\/science.7542804"},{"key":"bibr37-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1177\/135965359900400203"},{"key":"bibr38-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02223-21"},{"key":"bibr39-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014638"},{"key":"bibr40-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2008.10.008"},{"key":"bibr41-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1086\/510533"},{"key":"bibr42-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00676-y"},{"key":"bibr43-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20442-3"},{"key":"bibr44-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832ba8ec"},{"key":"bibr45-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02406-20"},{"key":"bibr46-13596535231201162","volume-title":"Apretude (cabotegravir) summary of product characteristics","author":"ViiV Healthcare","year":"2021"},{"key":"bibr47-13596535231201162","doi-asserted-by":"publisher","DOI":"10.3390\/scipharm86040043"},{"key":"bibr48-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-022-00616-y"},{"key":"bibr49-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002496"},{"key":"bibr50-13596535231201162","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2019-11-4"},{"key":"bibr51-13596535231201162","volume-title":"NNRTI resistance notes","author":"Stanford University HIV Drug Resistance Database","year":"2022"},{"key":"bibr52-13596535231201162","doi-asserted-by":"publisher","DOI":"10.4102\/sajhivmed.v21i1.1023"},{"key":"bibr53-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30099-0"},{"key":"bibr54-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz347"},{"key":"bibr55-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00419-5"},{"key":"bibr56-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa988"},{"key":"bibr57-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003244"},{"key":"bibr58-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283612419"},{"key":"bibr59-13596535231201162","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3166"},{"key":"bibr60-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60084-2"},{"key":"bibr61-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1101\/2023.04.05.23288183"},{"key":"bibr62-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad020"},{"key":"bibr63-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002466"},{"key":"bibr64-13596535231201162","volume-title":"PI resistance notes","author":"Stanford University HIV Drug Resistance Database","year":"2022"},{"key":"bibr65-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh384"},{"key":"bibr66-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00536-8"},{"key":"bibr67-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx091"},{"key":"bibr68-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb00777.x"},{"key":"bibr69-13596535231201162","volume-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2022"},{"key":"bibr70-13596535231201162","unstructured":"Vercauteren J, Vandamme A-M, Rossetti B, et al. Four-class resistance is rare in treatment-experienced patients across Europe. In: Conference on Retroviruses and Opportunistic Infections (CROI). Virtual. 2020."},{"key":"bibr71-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw128"},{"key":"bibr72-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002635"},{"key":"bibr73-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30240-X"},{"key":"bibr74-13596535231201162","volume-title":"Rukobia (Fostemsavir) summary of product characteristics","author":"ViiV Healthcare BV","year":"2021"},{"key":"bibr75-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa073"},{"key":"bibr76-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001602"},{"key":"bibr77-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711460"},{"key":"bibr78-13596535231201162","volume-title":"Trogarzo","author":"European Medicines Agency","year":"2023"},{"key":"bibr79-13596535231201162","volume-title":"Theratechnologies to focus its commercialization activities on the North American territory","author":"Theratechnologies Inc","year":"2022"},{"key":"bibr80-13596535231201162","volume-title":"Sunlenca (lenacapavir) summary of product characteristics","author":"Gilead Sciences Ireland UC","year":"2022"},{"key":"bibr81-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115542"},{"key":"bibr82-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13446"},{"key":"bibr83-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2004.02.015"},{"key":"bibr84-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00449-06"},{"key":"bibr85-13596535231201162","doi-asserted-by":"publisher","DOI":"10.3390\/v12070694"},{"key":"bibr86-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky315"},{"key":"bibr87-13596535231201162","doi-asserted-by":"publisher","DOI":"10.3390\/v12060617"},{"key":"bibr88-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283560703"},{"key":"bibr89-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1086\/650538"},{"key":"bibr90-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2019.05.004"},{"key":"bibr91-13596535231201162","unstructured":"University of Liverpool. Drug-Drug interaction checker, 2023, https:\/\/www.hiv-druginteractions.org\/ (accessed 27 March 2023)."},{"key":"bibr92-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001623"},{"key":"bibr93-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad219"},{"key":"bibr94-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1614"},{"key":"bibr95-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13444"},{"key":"bibr96-13596535231201162","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S28482"},{"key":"bibr97-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-020-00275-2"},{"key":"bibr98-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2020-054551"},{"key":"bibr99-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00853-06"},{"key":"bibr100-13596535231201162","first-page":"5447","volume":"9","author":"Woollard SM","year":"2015","journal-title":"Drug Des Dev Ther"},{"key":"bibr101-13596535231201162","doi-asserted-by":"publisher","DOI":"10.3390\/v12030297"},{"key":"bibr102-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1000766"},{"key":"bibr103-13596535231201162","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac364"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535231201162","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13596535231201162","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535231201162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:53:12Z","timestamp":1777380792000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/13596535231201162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,25]]},"references-count":103,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1177\/13596535231201162"],"URL":"https:\/\/doi.org\/10.1177\/13596535231201162","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,25]]},"article-number":"13596535231201162"}}